Figure S7 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Co-targeting bcl-xl and mcl-1 results in significant morphological changes in organoids after treatment.
• The treatment with BH3 mimetics leads to observable effects, supporting synergistic interactions between agents.
• Analysis of LuCaP-167CR organoids highlights the potential benefits of combined therapies in cancer treatment.
• These findings may enable improved strategies for targeting resistant prostate cancer variants, enhancing treatment outcomes.